AR122213A1 - Anticuerpos anti-cd200r1 y métodos de uso de estos - Google Patents
Anticuerpos anti-cd200r1 y métodos de uso de estosInfo
- Publication number
- AR122213A1 AR122213A1 ARP210101465A ARP210101465A AR122213A1 AR 122213 A1 AR122213 A1 AR 122213A1 AR P210101465 A ARP210101465 A AR P210101465A AR P210101465 A ARP210101465 A AR P210101465A AR 122213 A1 AR122213 A1 AR 122213A1
- Authority
- AR
- Argentina
- Prior art keywords
- cd200r1
- antibodies
- methods
- binding
- mediated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Proteínas de fijación, tales como anticuerpos y fragmentos de fijación al antígeno, que se fijan específicamente a la proteína receptora CD200R1 humana (hu-CD200R1) y que son capaces de disminuir, inhibir y/o bloquear por completo los efectos inmunorreguladores mediados por hu-CD200R1. También métodos para usar los anticuerpos (y composiciones de estos) para tratar enfermedades y afecciones que responden a la disminución, inhibición y/o bloqueo de la función o actividad inmunorreguladora mediada por la fijación de CD200 a CD200R1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063032508P | 2020-05-29 | 2020-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122213A1 true AR122213A1 (es) | 2022-08-24 |
Family
ID=76624182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101465A AR122213A1 (es) | 2020-05-29 | 2021-05-31 | Anticuerpos anti-cd200r1 y métodos de uso de estos |
Country Status (17)
Country | Link |
---|---|
US (2) | US11787861B2 (es) |
EP (1) | EP4157461A1 (es) |
JP (1) | JP2023528375A (es) |
KR (1) | KR20230018425A (es) |
CN (1) | CN116323665A (es) |
AR (1) | AR122213A1 (es) |
AU (1) | AU2021281417A1 (es) |
BR (1) | BR112022024339A2 (es) |
CA (1) | CA3178417A1 (es) |
CL (1) | CL2022003296A1 (es) |
CO (1) | CO2022016860A2 (es) |
CR (1) | CR20220608A (es) |
IL (1) | IL298668A (es) |
MX (1) | MX2022014736A (es) |
PE (1) | PE20230460A1 (es) |
TW (1) | TW202210512A (es) |
WO (1) | WO2021243204A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202400651A (zh) * | 2022-05-19 | 2024-01-01 | 中國商和鉑醫藥(上海)有限責任公司 | 抗cd200r1抗體 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
IL146417A0 (en) * | 1999-05-13 | 2002-07-25 | Medical Res Council | Ox2 receptor homologs |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING A POLYPEPTIDE |
CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2623109C (en) * | 2005-10-14 | 2019-02-19 | Innate Pharma | Nk cell-depleting antibodies for treating immunoproliferative disorders |
TW200732350A (en) | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
BRPI0720841A2 (pt) | 2006-12-22 | 2014-03-04 | Schering Corp | Anticorpos para cd200r |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
WO2008145138A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering |
WO2008145137A2 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
JP2011516840A (ja) * | 2008-04-04 | 2011-05-26 | トリリウム セラピューティクス インコーポレーティッド | 可溶性cd200に関するアッセイ法 |
WO2015057906A1 (en) * | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
-
2021
- 2021-05-28 BR BR112022024339A patent/BR112022024339A2/pt unknown
- 2021-05-28 EP EP21735037.0A patent/EP4157461A1/en active Pending
- 2021-05-28 WO PCT/US2021/034852 patent/WO2021243204A1/en unknown
- 2021-05-28 US US17/333,963 patent/US11787861B2/en active Active
- 2021-05-28 CA CA3178417A patent/CA3178417A1/en active Pending
- 2021-05-28 CN CN202180038994.4A patent/CN116323665A/zh active Pending
- 2021-05-28 KR KR1020227045305A patent/KR20230018425A/ko unknown
- 2021-05-28 CR CR20220608A patent/CR20220608A/es unknown
- 2021-05-28 AU AU2021281417A patent/AU2021281417A1/en active Pending
- 2021-05-28 JP JP2022573152A patent/JP2023528375A/ja active Pending
- 2021-05-28 PE PE2022002743A patent/PE20230460A1/es unknown
- 2021-05-28 MX MX2022014736A patent/MX2022014736A/es unknown
- 2021-05-28 IL IL298668A patent/IL298668A/en unknown
- 2021-05-31 AR ARP210101465A patent/AR122213A1/es unknown
- 2021-05-31 TW TW110119701A patent/TW202210512A/zh unknown
-
2022
- 2022-11-23 CL CL2022003296A patent/CL2022003296A1/es unknown
- 2022-11-24 CO CONC2022/0016860A patent/CO2022016860A2/es unknown
-
2023
- 2023-08-24 US US18/455,181 patent/US20240018239A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2022003296A1 (es) | 2023-04-14 |
CR20220608A (es) | 2023-01-26 |
MX2022014736A (es) | 2023-03-23 |
BR112022024339A2 (pt) | 2022-12-27 |
PE20230460A1 (es) | 2023-03-10 |
US20240018239A1 (en) | 2024-01-18 |
JP2023528375A (ja) | 2023-07-04 |
US20210371521A1 (en) | 2021-12-02 |
CO2022016860A2 (es) | 2023-02-27 |
AU2021281417A1 (en) | 2022-12-08 |
WO2021243204A9 (en) | 2022-01-20 |
CA3178417A1 (en) | 2021-12-02 |
CN116323665A (zh) | 2023-06-23 |
IL298668A (en) | 2023-01-01 |
KR20230018425A (ko) | 2023-02-07 |
TW202210512A (zh) | 2022-03-16 |
EP4157461A1 (en) | 2023-04-05 |
WO2021243204A1 (en) | 2021-12-02 |
US11787861B2 (en) | 2023-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR117327A1 (es) | Anticuerpos anti-cd96 y métodos de uso de estos | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA202092933A1 (ru) | Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
BR112016003369A2 (pt) | diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
EA202091747A1 (ru) | Составы антитела b7-h4 | |
BR112015030892A2 (pt) | Proteína de ligação ao antígeno, anticorpo monoclonal, ácido nucleico recombinante, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma proteína de ligação ao antígeno ou anticorpo humanizado, e, método para produzir uma proteína de ligação ao antígeno | |
AR115963A1 (es) | Anticuerpos anti-il1rap y métodos de uso de estos | |
CL2023002108A1 (es) | Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso. | |
BR112017021484A2 (pt) | anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos | |
EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
CL2021001615A1 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos | |
EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
EA202193345A1 (ru) | Антитела к рецептору-1 натрийуретического пептида и способы их применения | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
BR112022009317A2 (pt) | Anticorpos de cd73 biparatópicos | |
ECSP22041860A (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
CO2022000832A2 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
CO2022016860A2 (es) | Anticuerpos anti-cd200r1 y métodos de uso de estos | |
EA202190647A1 (ru) | Антитела к klrg1 | |
AR093671A1 (es) | Anticuerpos monoclonales contra una proteina activada c (apc) | |
BR112022022353A2 (pt) | Composições e métodos para reprogramação de tcr usando proteínas de fusão específicas de cd70 |